$1 Billion Oncology Alliance Initiates First-in-Human Study of Enhanced Antibody for Treatment of Acute Myeloid Leukemia
27-Nov-2014 -
Oxford BioTherapeutics and Berlin Chemie/ Menarini Biotech/ Menarini Ricerche (belonging to Menarini Group) announced that they have initiated the first-in-human clinical study of OBT357 (MEN1112), an enhanced antibody for the treatment of acute myeloid leukemia (AML). This is the first of five ...
acute myeloid leukemia
antibodies
phase I studies